Literature DB >> 24909257

Metabolic syndrome and cortisol/DHEAS ratio in patients with bipolar disorder and schizophrenia.

Bjanka Vuksan-Ćusa1, Marina Sagud, Alma Mihaljević-Peleš, Nenad Jakšić, Miro Jakovljević.   

Abstract

The cortisol/DHEAS ratio has been found to predict different health outcomes. We examined the association between cortisol/DHEAS ratio and metabolic syndrome (MetS) in patients suffering from bipolar disorder and schizophrenia. The only subcomponent of MetS positively associated with the cortisol/DHEAS ratio was diastolic blood pressure. Possible reasons for this finding, as well as study limitations, are discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24909257

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  4 in total

Review 1.  Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis.

Authors:  Ting-Ting Wu; Yuan Chen; Yun Zhou; Dilare Adi; Ying-Ying Zheng; Fen Liu; Yi-Tong Ma; Xiang Xie
Journal:  J Am Heart Assoc       Date:  2017-05-05       Impact factor: 5.501

2.  Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia.

Authors:  Anastasiia S Boiko; Irina A Mednova; Elena G Kornetova; Nikolay A Bokhan; Arkadiy V Semke; Anton J M Loonen; Svetlana A Ivanova
Journal:  Neuropsychiatr Dis Treat       Date:  2020-04-22       Impact factor: 2.570

3.  Functional Status of Hypothalamic-Pituitary-Thyroid and Hypothalamic-Pituitary-Adrenal Axes in Hospitalized Schizophrenics in Shanghai.

Authors:  Yuncheng Zhu; Haifeng Ji; Lily Tao; Qing Cai; Fang Wang; Weidong Ji; Guohai Li; Yiru Fang
Journal:  Front Psychiatry       Date:  2020-02-27       Impact factor: 4.157

4.  The Relationship of Functional Status of Cortisol, Testosterone, and Parameters of Metabolic Syndrome in Male Schizophrenics.

Authors:  Yi Han; Haifeng Ji; Li Liu; Yuncheng Zhu; Xixi Jiang
Journal:  Biomed Res Int       Date:  2020-10-22       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.